A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-993X (Electronic) Linking ISSN: 14659921 NLM ISO Abbreviation: Respir Res Subsets: MEDLINE
    • Publication Information:
      Publication: 2001- : London : BioMed Central Ltd.
      Original Publication: London : Current Science Ltd., c2000-
    • Subject Terms:
      Antigens, Surface/*blood ; Lung Diseases, Interstitial/*blood ; Macrophages/*metabolism ; Monocytes/*metabolism ; Scleroderma, Systemic/*blood; Aged ; Biomarkers/blood ; Biomarkers/metabolism ; Cross-Sectional Studies ; Female ; Flow Cytometry/methods ; Follow-Up Studies ; Humans ; Lung Diseases, Interstitial/diagnosis ; Lung Diseases, Interstitial/epidemiology ; Male ; Middle Aged ; Respiratory Function Tests/trends ; Scleroderma, Systemic/diagnosis ; Scleroderma, Systemic/epidemiology
    • Abstract:
      Background: Systemic sclerosis (SSc) is a disorder characterized by immune system alterations, vasculopathy and fibrosis. SSc-related interstitial lung disease (ILD) represents a common and early complication, being the leading cause of mortality. Monocytes/macrophages seem to have a key role in SSc-related ILD. Interestingly, the classically (M1) and alternatively (M2) activated monocyte/macrophage phenotype categorization is currently under revision. Our aim was to evaluate if circulating monocyte/macrophage phenotype could be used as biomarker for lung involvement in SSc. To this purpose we developed a wide phenotype characterization of circulating monocyte/macrophage subsets in SSc patients and we evaluated possible relations with lung involvement parameter values.
      Methods: A single centre cross-sectional study was performed in fifty-five consecutive SSc patients, during the year 2017. All clinical and instrumental tests requested for SSc follow up and in particular, lung computed tomography (CT) scan, pulmonary function tests (PFTs), Doppler echocardiography with systolic pulmonary artery pressure (sPAP) measurement, blood pro-hormone of brain natriuretic peptide (pro-BNP) evaluation, were performed in each patient in a maximum one-month period. Flow cytometry characterization of circulating cells belonging to the monocyte/macrophage lineage was performed using specific M1 (CD80, CD86, TLR2 and TLR4) and M2 surface markers (CD204, CD163 and CD206). Non-parametric tests were used for statistical analysis.
      Results: A higher percentage of circulating CD204 + CD163 + CD206 + TLR4 + CD80 + CD86 + and CD14 + CD206 + CD163 + CD204 + TLR4 + CD80 + CD86 + mixed M1/M2 monocyte/macrophage subsets, was identified to characterize patients affected by SSc-related ILD and higher systolic pulmonary artery pressure. Mixed M1/M2 monocyte/macrophage subset showed higher percentages in patients positive for anti-topoisomerase antibody, a known lung involvement predictor.
      Conclusions: The present study shows for the first time, through a wide flow cytometry surface marker analysis, that higher circulating mixed M1/M2 monocyte/macrophage cell percentages are associated with ILD, sPAP and anti-topoisomerase antibody positivity in SSc, opening the path for research on their possible role as pathogenic or biomarker elements for SSc lung involvement.
    • References:
      Cytometry B Clin Cytom. 2016 Jan;90(1):31-9. (PMID: 25619868)
      Oncoimmunology. 2012 Aug 1;1(5):770-772. (PMID: 22934278)
      Arthritis Rheum. 2013 Nov;65(11):2737-47. (PMID: 24122180)
      Arthritis Res Ther. 2010;12(4):R128. (PMID: 20602758)
      Arthritis Rheum. 2011 Jun;63(6):1718-28. (PMID: 21425123)
      Nature. 2011 Jun 08;475(7355):222-5. (PMID: 21654748)
      Curr Rheumatol Rep. 2016 Jan;18(1):2. (PMID: 26700912)
      J Autoimmun. 2013 Mar;41:161-7. (PMID: 23415078)
      Immunobiology. 2017 Feb;222(2):188-197. (PMID: 27720434)
      PLoS One. 2013 Oct 18;8(10):e78001. (PMID: 24205063)
      Ann Rheum Dis. 2018 Apr;77(4):596-601. (PMID: 29348297)
      Ann Rheum Dis. 2018 Jul 16;:null. (PMID: 30012643)
      J Autoimmun. 2010 Mar;34(2):155-62. (PMID: 19796918)
      J Invest Dermatol. 2018 Oct;138(10):2123-2132. (PMID: 29689251)
      Rheumatology (Oxford). 2009 Mar;48(3):304-8. (PMID: 19174571)
      Arthritis Rheumatol. 2014 Mar;66(3):714-25. (PMID: 24574232)
      Lancet. 1991 Sep 14;338(8768):661-2. (PMID: 1679476)
      Respir Res. 2018 Apr 18;19(1):66. (PMID: 29669565)
      Nat Rev Immunol. 2011 Mar;11(3):221-30. (PMID: 21350581)
      Nat Rev Immunol. 2014 Aug;14(8):571-8. (PMID: 25033907)
      J Autoimmun. 2014 Feb-Mar;48-49:38-41. (PMID: 24461384)
      J Rheumatol. 2013 Dec;40(12):2023-8. (PMID: 24128778)
      J Pathol. 2013 Jan;229(2):176-85. (PMID: 23096265)
      J Comput Assist Tomogr. 2001 Sep-Oct;25(5):757-63. (PMID: 11584237)
      Dis Markers. 2018 Apr 1;2018:8509583. (PMID: 29805720)
      Proc Am Thorac Soc. 2007 Aug 15;4(5):434-8. (PMID: 17684284)
      Int J Radiat Biol. 2016 Dec;92(12):754-765. (PMID: 27539247)
      Immunology. 2013 Sep;140(1):22-30. (PMID: 23621371)
      Toxicol Sci. 2018 Jun 1;163(2):454-465. (PMID: 29471534)
      J Autoimmun. 2006 Jun;26(4):258-67. (PMID: 16735104)
      Genome Med. 2017 Mar 23;9(1):27. (PMID: 28330499)
      Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248-54. (PMID: 18369202)
      PLoS One. 2015 Jan 21;10(1):e0114017. (PMID: 25607805)
      J Asthma Allergy. 2016 Jun 03;9:101-7. (PMID: 27350756)
      Arthritis Rheum. 2011 Mar;63(3):783-94. (PMID: 21360508)
      Respir Res. 2005 Aug 10;6:92. (PMID: 16092961)
      Nat Rev Rheumatol. 2017 Jul;13(7):443-448. (PMID: 28615732)
      Cytometry B Clin Cytom. 2017 May;92(3):180-188. (PMID: 26332381)
      Ann Rheum Dis. 2017 Nov;76(11):1897-1905. (PMID: 28835464)
      Arthritis Res Ther. 2017 Jan 19;19(1):9. (PMID: 28103926)
      Nat Rev Immunol. 2008 Dec;8(12):958-69. (PMID: 19029990)
      Clin Rheumatol. 2017 Jul;36(7):1649-1654. (PMID: 28293753)
      Int J Mol Sci. 2018 Mar 17;19(3):null. (PMID: 29562615)
      Nat Rev Immunol. 2011 Oct 10;11(11):738-49. (PMID: 21984069)
      Blood. 2014 May 15;123(20):e110-22. (PMID: 24695852)
      Respir Res. 2017 Feb 23;18(1):40. (PMID: 28231829)
      Ann Rheum Dis. 2018 Feb 9;:null. (PMID: 29439999)
      Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S66-74. (PMID: 21586221)
      Int J Cardiol. 2017 Jun 1;236:432-437. (PMID: 28159359)
    • Contributed Indexing:
      Keywords: Anti-topoisomerase antibody; Flow cytometry; Innate immunity; Interstitial lung disease; Lung CT scan; M1; M2; Monocyte/macrophage phenotype; Pulmonary artery hypertension; Pulmonary function tests; Systemic sclerosis
    • Accession Number:
      0 (Antigens, Surface)
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20180926 Date Completed: 20190225 Latest Revision: 20190225
    • Publication Date:
      20221213
    • Accession Number:
      PMC6154930
    • Accession Number:
      10.1186/s12931-018-0891-z
    • Accession Number:
      30249259